[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636153":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":32,"centralContacts":39,"locations":44,"responsibleParty":64,"collaborators":22,"id":66,"slug":22,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":22,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":91,"whyStopped":22,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Sichuan Cancer Hospital and Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tislelizumab Plus Chemotherapy and BACE","EXPERIMENTAL","Participants receive tislelizumab, intravenous chemotherapy, and bronchial artery chemoembolization (BACE) as conversion therapy. Tislelizumab 200 mg is administered intravenously on Day 0 of each 21-day cycle. On Day 1, participants receive intravenous chemotherapy (albumin-bound paclitaxel for lung squamous cell carcinoma or pemetrexed for lung adenocarcinoma) and BACE with intra-arterial carboplatin plus 300-500 μm blank microspheres. Conversion treatment is given for up to 4 cycles. The number of BACE procedures ranges from 1 to 4 and is determined by tumor response and multidisciplinary team assessment. Participants who become resectable may undergo surgery followed by protocol-defined postoperative treatment. Participants who remain unresectable after 4 cycles may receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation.",[13,14,15],"Drug: Tislelizumab","Drug: Intravenous Chemotherapy","Procedure: Bronchial Artery Chemoembolization (BACE)",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Tislelizumab","Tislelizumab 200 mg is administered intravenously on Day 0 of each 21-day cycle for up to 4 cycles. Postoperative or consolidation tislelizumab may be given according to protocol-defined treatment pathways.",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Intravenous Chemotherapy","Intravenous chemotherapy is administered on Day 1 of each 21-day cycle for up to 4 cycles. Patients with lung squamous cell carcinoma receive albumin-bound paclitaxel, and patients with lung adenocarcinoma receive pemetrexed. Carboplatin is administered intra-arterially during BACE in cycles with the procedure; if BACE is not performed in a given cycle, carboplatin is administered intravenously on the same day per protocol.",[9],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"PROCEDURE","Bronchial Artery Chemoembolization (BACE)","BACE is performed on Day 1 of the first 21-day treatment cycle using intra-arterial carboplatin infusion followed by embolization with 300-500 μm blank microspheres. Subsequent BACE procedures are performed on demand, based on tumor response on contrast-enhanced chest CT and multidisciplinary team (MDT) evaluation. The total number of BACE procedures ranges from 1 to 4.",[9],[33,36],{"name":34,"affiliation":5,"role":35},"Xuegang Yang, MD","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":5,"role":38},"Guohui Xu, MD","STUDY_CHAIR",[40],{"name":34,"role":41,"phone":42,"phoneExt":22,"email":43},"CONTACT","+8613683476844","yanggangxue@163.com",[45],{"facility":5,"status":22,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Chengdu","Sichuan","610041","China","CN",{"type":52,"coordinates":53},"Point",[54,55],104.06667,30.66667,{"lat":55,"lon":54},[58,62,63],{"name":59,"role":41,"phone":60,"phoneExt":22,"email":61},"Guohui Xu","+8613708010123","xgh0913@hotmail.com",{"name":34,"role":41,"phone":42,"phoneExt":22,"email":43},{"name":34,"role":35,"phone":22,"phoneExt":22,"email":22},{"type":35,"investigatorFullName":59,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Principal Investigator, Chief Physician, Director of Department of Interventional Therapy","100636153",false,"NCT07561983","Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC","Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)","BEACON-Lung","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n* Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system\n* Initially unresectable disease as determined by multidisciplinary team (MDT) assessment\n* At least 1 measurable intrapulmonary lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Forced expiratory volume in the first second (FEV1) \\> 1.0 L and \\> 40% of predicted normal value\n* Estimated life expectancy of at least 3 months\n* Adequate organ function\n* Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment\n* Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Ability to understand and willingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Prior local therapy for NSCLC, including radiotherapy or interventional therapy\n* Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations\n* Distant organ metastasis\n* History of another malignancy within the past 5 years\n* Active autoimmune disease or history of autoimmune disease requiring systemic treatment\n* Known allergy to any study drug or excipient\n* Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis\n* Major surgery requiring general anesthesia within 4 weeks before first dose\n* Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk\n* Participation in another interventional therapeutic clinical study\n* Psychiatric illness or history of psychotropic drug abuse that may compromise study participation\n* Any condition judged by the investigator to make the patient unsuitable for the study","ALL","18 Years","80 Years",{"count":77,"type":78},39,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:\n\n* What is the 1-year event-free survival (EFS) rate with this treatment?\n* Can this treatment improve tumor response and the chance of curative-intent resection?\n* What adverse events occur during treatment?\n\nParticipants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.",[84,19,85,86,87],"Unresectable Stage III Non-small Cell Lung Cancer","Chemotherapy","Chemoembolization, Therapeutic","Conversion Therapy",[89,19,85,90,87],"Unresectable Non-Small Cell Lung Cancer","Bronchial Artery Chemoembolization","NOT_YET_RECRUITING","2026-04-24",{"date":94,"type":95},"2026-05-01","ACTUAL",{"date":94,"type":78},{"date":98,"type":78},"2028-12-31",{"name":5,"class":6},1]